Hofseth BioCare’s peer‑reviewed ProGo study demonstrates GLP‑1‑like effects and increased lean muscle mass, strengthening its position in the functional protein market
Executive summary: Hofseth BioCare ASA announced the publication of a randomized, double‑blind, active‑controlled pilot study in the journal Biomedicines showing that 56 days of daily ProGo® salmon protein hydrolysate yielded GLP‑1 benefits and an increase in lean muscle mass. The results provide peer‑reviewed evidence for health‑related claims that can be used to differentiate ProGo in the competitive nutraceutical sector and support potential applications in metabolic health.
Who is involved: Hofseth BioCare ASA (HBC), the study investigators, and the Biomedicines editorial team.
Likely next: The study will be available for HBC to cite in marketing materials and regulatory filings for ProGo.
Hofseth BioCare ASA announced the publication of a randomized, double‑blind, active‑controlled pilot study in the journal Biomedicines. The trial found that 56 days of daily ProGo® salmon protein hydrolysate produced measurable GLP‑1 benefits and an increase in lean muscle mass among participants. The peer‑reviewed result gives the company scientific backing for health‑related claims on its ingredient and may influence how ProGo is positioned in the nutraceutical and functional‑food sectors.
Timeline
- — Hofseth BioCare ASA: NEW PEER-REVIEWED CLINICAL STUDY ON PROGO® PUBLISHED IN BIOMEDINES DEMONSTRATES GLP-1 BENEFITS AND AN INCREASE LEAN MUSCLE MASS (GlobeNewswire)
Analysis — what this means
Sectors affected
- salmon protein hydrolysate supplements
- nutraceuticals
- functional foods
Regulatory implications
- The study data can be cited in applications for nutrition and health claims under EU Regulation 1924/2006.
Key entities
Sources
Related cases
- Citizens Bank of Edmond gains a seat at the G20 private‑sector table, boosting its influence on main‑street growth discussions
- Lindian Resources secures 10‑year offtake and tech services deal with Carester to develop oxide separation capacity
- Lindian Resources secures a 10‑year offtake and technology partnership with Carester to develop oxide separation capabilities, locking in long‑term revenue for its rare‑earth project
- Luke Dashjr's departure from OCEAN triggers a leadership shift and equity buyback that could reshape the company's strategic direction
- Tezspire’s positive Phase 3 eosinophilic esophagitis data open a new growth avenue for the asthma biologic
- YinzCam teams with Halo23 to expand its unified digital sports platform into the GCC, Australia and New Zealand